Application

A-967079 has been used in blocking miR-711-induced TRPA1 (transient receptor potential cation channel subfamily A member 1) channel.

Biochem/physiol Actions

A-967079 is a potent and selective antagonist of Transient Receptor Potential Anykrin 1 (TRPA1) with IC₅₀′s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and minimal or no activity at other TRP channels or G-protein-coupled receptors, enzymes, transporters, and ion channels out of 89 tested. A-967079 blocks TRPA1 activation in human and rat cell lines and has been shown to reduce the responses of wide dynamic range (WDR) and nociceptive specific (NS) neurons to high-intensity mechanical stimulation.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

A-967079 prevents neuropathic and inflammatory pain. It reduces cold allodynia, which is produced by nerve injury.

Packaging

5, 25 mg in glass bottle